216 related articles for article (PubMed ID: 21042215)
1. A comparison of international guidelines for the prevention of chemotherapy-induced neutropenia.
Lyman GH
Curr Opin Hematol; 2011 Jan; 18(1):1-10. PubMed ID: 21042215
[TBL] [Abstract][Full Text] [Related]
2. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
Cancer Treat Res; 2011; 157():145-65. PubMed ID: 21052955
[TBL] [Abstract][Full Text] [Related]
3. Granulocyte colony-stimulating factors: finding the right indication.
Lyman GH; Shayne M
Curr Opin Oncol; 2007 Jul; 19(4):299-307. PubMed ID: 17545791
[TBL] [Abstract][Full Text] [Related]
4. Use of granulocyte colony-stimulating factor (G-CSF) in patients receiving myelosuppressive chemotherapy for the treatment of cancer. Provincial Systemic Treatment Disease Site Group.
Rusthoven J; Bramwell V; Stephenson B
Cancer Prev Control; 1998 Aug; 2(4):179-90. PubMed ID: 10093631
[TBL] [Abstract][Full Text] [Related]
5. Oncology nurses' use of National Comprehensive Cancer Network clinical practice guidelines for chemotherapy-induced and febrile neutropenia.
Nirenberg A; Reame NK; Cato KD; Larson EL
Oncol Nurs Forum; 2010 Nov; 37(6):765-73. PubMed ID: 21059588
[TBL] [Abstract][Full Text] [Related]
6. Shifting guidelines for myeloid growth factors: applications in cancer chemotherapy.
Daniel DB; Crawford J;
Curr Hematol Rep; 2005 Nov; 4(6):441-5. PubMed ID: 16232380
[TBL] [Abstract][Full Text] [Related]
7. Summary and comparison of myeloid growth factor guidelines in patients receiving cancer chemotherapy.
Lyman GH; Kleiner JM
J Natl Compr Canc Netw; 2007 Feb; 5(2):217-28. PubMed ID: 17335690
[TBL] [Abstract][Full Text] [Related]
8. First-Cycle CSF use in breast cancer and NHL: guidelines and recommendations.
Al-Kali A; Ozer H
Oncology (Williston Park); 2006 Dec; 20(14 Suppl 9):7-12. PubMed ID: 17370923
[TBL] [Abstract][Full Text] [Related]
9. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines.
J Clin Oncol; 1994 Nov; 12(11):2471-508. PubMed ID: 7964965
[TBL] [Abstract][Full Text] [Related]
10. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract][Full Text] [Related]
11. Clinical practice guidelines for the use of colony-stimulating factors in cancer treatment: Implications for oncology nurses.
Kearney N; Friese C
Eur J Oncol Nurs; 2008 Feb; 12(1):14-25. PubMed ID: 18291720
[TBL] [Abstract][Full Text] [Related]
12. Nurses' guide to understanding and implementing the National Comprehensive Cancer Network guidelines for myeloid growth factors.
Wilson BJ; Gardner AE
Oncol Nurs Forum; 2007 Mar; 34(2):347-53. PubMed ID: 17573299
[TBL] [Abstract][Full Text] [Related]
13. Febrile neutropenia: highlighting the role of prophylactic antibiotics and granulocyte colony-stimulating factor during standard dose chemotherapy for solid tumors.
Timmer-Bonte JN; Tjan-Heijnen VC
Anticancer Drugs; 2006 Sep; 17(8):881-9. PubMed ID: 16940798
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment in oncology clinical practice. From risk factors to risk models.
Lyman GH
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 11):8-13. PubMed ID: 14682113
[TBL] [Abstract][Full Text] [Related]
15. Risk assessment and guidelines for first-cycle colony-stimulating factor use in the management of chemotherapy-induced neutropenia.
Crawford J
Oncology (Williston Park); 2006 Apr; 20(5 Suppl 4):22-8. PubMed ID: 16736985
[TBL] [Abstract][Full Text] [Related]
16. Treatment strategies for myeloid growth factors and intravenous iron: when, what, and how?
Crawford J; Rodgers GM
J Natl Compr Canc Netw; 2014 May; 12(5 Suppl):821-4. PubMed ID: 24853225
[TBL] [Abstract][Full Text] [Related]
17. Granulocyte growth factors in the treatment of non-small cell lung cancer (NSCLC).
Grossi F; Tiseo M
Crit Rev Oncol Hematol; 2006 Jun; 58(3):221-30. PubMed ID: 16697211
[TBL] [Abstract][Full Text] [Related]
18. Use of colony-stimulating factors for chemotherapy-associated neutropenia: review of current guidelines.
Heuser M; Ganser A; Bokemeyer C; ; ;
Semin Hematol; 2007 Jul; 44(3):148-56. PubMed ID: 17631179
[TBL] [Abstract][Full Text] [Related]
19. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
Crawford J; Becker PS; Armitage JO; Blayney DW; Chavez J; Curtin P; Dinner S; Fynan T; Gojo I; Griffiths EA; Hough S; Kloth DD; Kuter DJ; Lyman GH; Mably M; Mukherjee S; Patel S; Perez LE; Poust A; Rampal R; Roy V; Rugo HS; Saad AA; Schwartzberg LS; Shayani S; Talbott M; Vadhan-Raj S; Vasu S; Wadleigh M; Westervelt P; Burns JL; Pluchino L
J Natl Compr Canc Netw; 2017 Dec; 15(12):1520-1541. PubMed ID: 29223990
[TBL] [Abstract][Full Text] [Related]
20. Should the indications for the use of myeloid growth factors for the prevention of febrile neutropenia in cancer patients be extended?
Klastersky J; Awada A; Aoun M; Paesmans M
Curr Opin Oncol; 2009 Jul; 21(4):297-302. PubMed ID: 19509500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]